罗欣药业(002793) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥621,681,834.57, representing an increase of 8.87% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥176,660,541.04, a decrease of 72.14% year-over-year[2]. - Total operating revenue for Q3 2024 reached ¥1,880,916,973.62, an increase from ¥1,826,505,219.29 in the same period last year, reflecting a growth of approximately 2.98%[13]. - The net profit for Q3 2024 was -317.60 million, compared to -286.58 million in Q3 2023, indicating a year-over-year decline of approximately 10.8%[14]. - The basic earnings per share for Q3 2024 was -0.25, compared to -0.21 in Q3 2023, indicating a worsening in earnings per share[15]. - The total comprehensive income for Q3 2024 was -317.39 million, compared to -280.68 million in Q3 2023, reflecting an increase in losses of approximately 13.1%[15]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was -¥162,463,515.99, a decline of 151.26% compared to the previous year[5]. - The cash inflow from operating activities was 1.87 billion, down from 2.19 billion, indicating a decrease of approximately 14.9%[16]. - The net cash outflow from operating activities was CNY 162,463,515.99, compared to a net inflow of CNY 316,945,306.52 in the previous year, indicating a significant decline in operational cash flow[17]. - The total cash and cash equivalents at the end of the period stood at CNY 339,664,127.93, down from CNY 734,401,426.60 at the end of the previous year[17]. - The cash paid to employees was CNY 472,354,987.52, a decrease from CNY 500,408,359.45 in the previous year, suggesting cost-cutting measures[17]. Assets and Liabilities - The total assets as of September 30, 2024, were ¥4,889,277,306.84, down 4.46% from the end of the previous year[2]. - Current liabilities rose significantly to ¥2,406,832,950.04, compared to ¥1,917,555,795.86, marking an increase of around 25.49%[12]. - Non-current liabilities decreased to ¥328,402,186.29 from ¥627,442,216.48, a reduction of about 47.7%[12]. - The company's equity attributable to shareholders decreased by 14.81% to ¥2,104,123,686.23 compared to the end of the previous year[2]. Investment and Expenditures - Research and development expenses for the year-to-date period were ¥49,206,243.34, a reduction of 46.03% compared to the same period last year[5]. - The company reported a significant decrease in investment income, with a loss of -¥12,337,516.69, down 918.53% year-over-year[5]. - Development expenditures increased to ¥256,741,195.40 from ¥224,910,329.08, showing a growth of about 14.18%[12]. - Total cash outflow from investment activities was CNY 96,664,625.59, down from CNY 181,021,835.92 year-over-year, reflecting a reduction in investment expenditures[17]. - Cash received from investment activities totaled CNY 115,027,930.59, a significant decrease from CNY 1,223,468,002.36 year-over-year, highlighting reduced investment returns[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,202[6]. - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., holds 21.79% of shares, totaling 236,955,520 shares[6]. - The company has a total of 2.39% of its total share capital held in its repurchase account[7]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest five shareholders holding over 50%[7]. Operational Challenges - The company experienced a 70.35% increase in short-term borrowings, totaling ¥946,486,153.68[4]. - The company reported an investment loss of -12.34 million, a significant decline from a gain of 1.51 million in the previous year[14]. - Operating profit for Q3 2024 was -298.56 million, compared to -258.11 million in the same period last year, showing an increase in losses of approximately 15.7%[14]. - Sales expenses increased to 766.65 million from 686.20 million, marking an increase of about 11.7% year-over-year[14]. Audit and Compliance - The company did not undergo an audit for the third quarter report, indicating that the financial results are unaudited[18].